SCHEMBL830994

SCHEMBL830994

COc1ccc(CS(=O)(=O)c2cc3ccccc3sc2=O)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCKR Q14397 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.41
MAPK1 P28482 2/20 0.41
POLB P06746 1/20 0.41
GAA P10253 1/20 0.41
ALDH1A1 P00352 4/20 0.41
L3MBTL1 Q9Y468 3/20 0.41
CYP3A4 P08684 2/20 0.41
CYP2C19 P33261 2/20 0.41
CYP1A2 P05177 1/20 0.41
KMT2A Q03164 5/20 0.41
NPC1 O15118 1/20 0.40
TP53 P04637 1/20 0.40
MAPT P10636 1/20 0.40
HPGD P15428 1/20 0.40
ALOX15 P16050 1/20 0.40
TSHR P16473 1/20 0.40
NFKB1 P19838 1/20 0.40
RAB9A P51151 1/20 0.40
NFKB2 Q00653 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL830154 0.89 CA2 (0.49) POLBALDH1A1L3MBTL1CYP3A4CYP2C19
SCHEMBL830871 0.84 MEN1 (0.42) SMN1; SMN2MAPK1POLBALDH1A1L3MBTL1
SCHEMBL830672 0.84 SULT1A1 (0.43) SMN1; SMN2GAAALDH1A1L3MBTL1CYP3A4
SCHEMBL830855 0.84 CA2 (0.40) POLBL3MBTL1PLCG1
SCHEMBL830177 0.84 MEN1 (0.42) SMN1; SMN2MAPK1POLBGAAALDH1A1
SCHEMBL830657 0.83 KDM4E (0.41) MAPK1POLBALDH1A1CYP3A4CYP2C19
SCHEMBL830873 0.79 ALDH1A1 (0.43) SMN1; SMN2MAPK1POLBGAAALDH1A1
SCHEMBL830244 0.78 ALDH1A1 (0.45) SMN1; SMN2MAPK1POLBALDH1A1L3MBTL1
SCHEMBL829834 0.78 HTT (0.50) GCKRSMN1; SMN2MAPK1GAAALDH1A1
SCHEMBL830889 0.76 PARK7 (0.41) SMN1; SMN2POLBALDH1A1L3MBTL1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070232649-A1 Heteroaryl Sulfones and Sulfonamides and Therapeutic Uses Thereof TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2007-10-04 US claimed
EP-1765804-A2 HETEROARYL SULFONES AND SULFONAMIDES AND THERAPEUTIC USES THEREOF Temple University of the Commonwealth System of Higher Education (US) 2007-03-28 EP claimed
WO-2005123077-A2 HETEROARYL SULFONES AND SULFONAMIDES AND THERAPEUTIC USES THEREOF TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2005-12-29 WO claimed
US-8143428-B2 Heteroaryl sulfones and sulfonamides and therapeutic uses thereof TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2012-03-27 US disclosed
US-20070232649-A1 Heteroaryl Sulfones and Sulfonamides and Therapeutic Uses Thereof TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2007-10-04 US disclosed
EP-1765804-A2 HETEROARYL SULFONES AND SULFONAMIDES AND THERAPEUTIC USES THEREOF Temple University of the Commonwealth System of Higher Education (US) 2007-03-28 EP disclosed
WO-2005123077-A2 HETEROARYL SULFONES AND SULFONAMIDES AND THERAPEUTIC USES THEREOF TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2005-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232649-A1 Heteroaryl Sulfones and Sulfonamides and Therapeutic Uses Thereof SULT1E1, STS, CCNE1 GCKR 4535/4885SMN1; SMN2 1066/4885MAPK1 4502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.